At the 2022 Tandem Meetings, Nina Shah, MD, spoke about key findings from the phase 2 KarMMa trial that used idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma.
CancerNetwork® spoke with Nina Shah, MD, a hematologist oncologist from University of California San Francisco Health, as part of an interview during the 2022 Tandem Meeting about key results of the phase 2 KarMMA trial (NCT03361748) assessing idecabtagene vicleucel (ide-cel; Abecma) in patients with relapsed/refractory multiple myeloma who have received 4 or more lines of therapy.1 The upcoming presentation at the meeting will focus on patients who achieved a complete response in relation to treatment.
Shah highlighted how results from the trial led to the FDA approval for ide-cel in March 2021 in previously treated multiple myeloma.2 Patients had a median peak of CAR T-cell expression at 11 days and persistence was durable, with CAR T-cells being detected in 59% of patients at 6 months, and 36% at 12 months.
The phase 2 single-arm KarMMa [trial] was a study of [patients with] relapsed/refractory multiple myeloma who received single-agent BCMA-directed CAR T-cell therapy, also known as ide-cel. In this study, patients were heavily pretreated with 6 median prior lines of [therapy] and they were all refractory to their last treatment. We now know that at all dose levels, there was a response rate [of over 70%] with an overall median PFS [progression-free survival] of a little over 8 months.
CRS [cytokine release syndrome] was only [present] in 84% [of patients], but it was generally grade 1 or 2, and neurotoxicity occurred in about 18% of patients. Because of this, and some good quality of life data, [ide-cel] was ultimately FDA approved for patients with relapsed/refractory multiple myeloma with at least 4 prior lines of therapy.
Relapsed/Refractory Multiple Myeloma Trial Updates From ASCO 2023
August 7th 2023Experts from Mayo Clinic and The University of Texas MD Anderson Cancer Center discuss results from multiple myeloma trials presented at the 2023 American Society of Clinical Oncology Annual Meeting and how they may apply to clinical practice.